Taysha Gene Therapies (TSHA) announced details of its planned pivotal Part B trial design for TSHA-102 following written alignment from the FDA. Additionally, the company announced clinical data from Part A of the REVEAL Phase 1/2 adolescent/adult and pediatric trials evaluating TSHA-102 in Rett syndrome. The alignment reached with the FDA was supported by the company’s analysis of the International Rett Syndrome Foundation’s longitudinal Rett syndrome natural history study data, as well as clinical data from the ongoing REVEAL Phase 1/2 trials.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TSHA:
- Taysha Gene Therapies announces common stock offering, no amount given
- Positive Developments and Strategic Moves Position Taysha Gene Therapies for Success with TSHA-102
- Taysha Gene Therapies price target raised to $9 from $8 at Canaccord
- Taysha Gene Therapies: Promising FDA Alignment and Strong Financials Justify Buy Rating
- Taysha Gene Therapies Advances in Rett Syndrome Trials